The PennZone

  • Home
  • Books
  • Entertainment
  • Marketing
  • Non-profit
  • Music
  • Education
  • Health
  • Business

HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
The PennZone/10270943

Trending...
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.

The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.

More on The PennZone
  • Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
  • YWCA Hanover to Host 7th Annual EMERGE Women's Conference
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Is Your Home Buyer REALLY Qualified?
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing

The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.

HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Sawgrass Ford President Attributes Dealerships Success to Long-Term Employees
  • New Children's Book "Frolly Found a Dolly in the Park" Celebrates Empathy and the Joy of Help
  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
  • Can Government Operate Better Through Innovation?
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Pittsburgh Creators Launch Clever New Children's Book, "The Sock Sleuth!"
  • Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off
  • Fashion vs. Fascism - Because Democracy Should Always Be In Style
  • Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 228
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions - 200
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 193
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man - 186
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 176
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event - 159
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers - 153
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 150
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala - 144
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300 - 125

Similar on PennZone

  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Can Government Operate Better Through Innovation?
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us